Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 12/20 | 0.62 |
| ▸ | DRD2 | P14416 | 11/20 | 0.62 |
| ▸ | DRD4 | P21917 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10247281 | 1.00 | DRD3 (0.62) | DRD3DRD2DRD4MEN1KMT2A | |
| SCHEMBL24540244 | 0.92 | OPRK1 (0.62) | DRD3DRD2DRD4MEN1KMT2A | |
| SCHEMBL629321 | 0.92 | OPRK1 (0.62) | DRD3DRD2DRD4MEN1KMT2A | |
| SCHEMBL18566685 | 0.92 | OPRK1 (0.62) | DRD3DRD2DRD4MEN1KMT2A | |
| SCHEMBL23474196 | 0.88 | DRD2 (0.56) | DRD3DRD2DRD4MEN1KMT2A | |
| SCHEMBL13799411 | 0.84 | DRD2 (0.50) | DRD3DRD2DRD4MEN1KMT2A | |
| SCHEMBL13799412 | 0.81 | HTR2A (0.46) | DRD3DRD2DRD4HTR1A | |
| SCHEMBL2564622 | 0.78 | DRD3 (0.65) | DRD3DRD2DRD4MEN1KMT2A | |
| SCHEMBL30199160 | 0.78 | DRD3 (0.65) | DRD3DRD2DRD4MEN1KMT2A | |
| SCHEMBL597666 | 0.78 | SRD5A1 (0.42) | DRD3DRD2DRD4LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022133027-A1 | SUBSTITUTED CYCLOHEXANECARBOXAMIDES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2022-06-23 | — | — | WO | disclosed |
| US-20140256947-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20100197924-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197924-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MAP4K5, MAP4K2, MAP4K1 | DRD3 1669/4885DRD2 1302/4885DRD4 1175/4885 |
| US-20140256947-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MAP4K5, MAP4K2, MAP4K1 | DRD3 1669/4885DRD2 1302/4885DRD4 1175/4885 |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | DRD3 2383/4885DRD2 2063/4885DRD4 2585/4885 |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | DRD3 2036/4885DRD2 1964/4885DRD4 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.